ArticleJournal of clinical neurology (Seoul, Korea)2026
Efficacy and Safety of Nipocalimab in Adults With Generalised Myasthenia Gravis: An Asian Subgroup Analysis of the Vivacity-MG3 Study.
Article in Journal of clinical neurology (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
background and purposeThe phase 3, randomised, double-blind, placebo-controlled Vivacity-MG3 trial demonstrated that nipocalimab, a neonatal Fc receptor blocker, provided sustained disease control over 6 months when added to standard of care therapies in patients with antibody-positive generalised myasthenia gravis (gMG). Here we present the Vivacity-MG3 Asian subgroup analysis.
methodsRecruited patients were randomised (1:1) to receive either nipocalimab (30 mg/kg loading dose, then 15 mg/kg every 2 weeks for maintenance) or placebo infusions every 2 weeks, both alongside standard of care therapy, for 24 weeks. The primary endpoint was the difference between nipocalimab and placebo groups in least-squares mean change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score over weeks 22-24 in seropositive patients. Other endpoints included changes in Quantitative Myasthenia Gravis (QMG) score and MG-ADL response rates. Adverse events were evaluated in all treated patients.
resultsThis analysis included 56 patients from East Asia (nipocalimab
conclusionsNipocalimab demonstrated a favourable efficacy and safety in the East Asian subgroup, with outcomes generally consistent with the overall Vivacity-MG3 study, supporting its role as a treatment option for gMG in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.